Table 2 Assessment method of administration of included studies
Study | Trial group (N) | Control Group(N) | Interventions (Groups) | Treatment cycle | Termination of treatment | |
|---|---|---|---|---|---|---|
Cisplatin+IL-2 | Cisplatin alone | |||||
Changjie H 2001 [15] | 30 | 30 | Cisplatin: 50 mg + NS 50 mL IL-2: 2 million units+NS 30 mL | Cisplatin 50 mg + NS 50 mL | 1/week | > 2 cycles, or pleural effusion disappeared |
Xiuzhi Y 2001 [16] | 40 | 20 | Cisplatin: 40 mg + NS 50 mL IL-2: 2 million units+NS 30 mL | Cisplatin 40 mg + NS 50 mL | 1/week | > 2 cycles, or pleural effusion disappeared |
Zhuo S 2004 [17] | 32 | 30 | Cisplatin: 60 mg + NS 30 mL IL-2: 2 million units+NS 30 mL | Cisplatin 60 mg + NS 30 mL | 1/week | > 2 cycles, or pleural effusion disappeared |
Junyan W 2005 [18] | 48 | 34 | Cisplatin: 80-100 mg + NS 30 mL IL-2: 2–3 million units+NS 30 mL | Cisplatin 80-100 mg + NS 30 mL | 1/week | > 3 cycles, or pleural effusion disappeared |
Haiying X 2009 [19] | 35 | 28 | Cisplatin: 60 mg + NS 40 mL IL-2: 2 million units+NS 20 mL | Cisplatin 60 mg + NS 40 mL | 1/week | > 2 cycles, or pleural effusion disappeared |
Xiaoxia H 2009 [20] | 37 | 35 | Cisplatin: 100 mg + NS 50 mL IL-2: 1 million units+NS 30 mL | Cisplatin 100 mg + NS 50 mL | 1/week | > 2 cycles, or pleural effusion disappeared |
Lizheng C 2009 [21] | 46 | 40 | Cisplatin: 50 mg + NS 50 mL IL-2: 2–3 million units+NS 50 mL | Cisplatin 50 mg + NS 50 mL | 1/week | > 2 cycles, or pleural effusion disappeared |
Jinguang C 2009 [22] | 31 | 31 | Cisplatin: 60 mg + NS 50 mL IL-2: 2 million units+NS 50 mL | Cisplatin 60 mg + NS 50 mL | 1/week | > 3 cycles, or pleural effusion disappeared |
Junfeng W 2010 [23] | 41 | 41 | Cisplatin: 60-80 mg + NS 50 mL IL-2: 2–3 million units+NS 50 mL | Cisplatin 60-80 mg + NS 50 mL | 1/week | > 3 cycles, or pleural effusion disappeared |
Jingping Z 2010 [24] | 63 | 61 | Cisplatin: 40-60 mg + NS 50 mL IL-2: 1 million units+NS 40 mL | Cisplatin 40–60 + NS 40 mL | 1/week | > 3 cycles, or pleural effusion disappeared |
Cheng X 2010 [25] | 31 | 31 | Cisplatin: 60-100 mg + NS 50 mL IL-2: 1–2 million units+NS 50 mL | Cisplatin 60-100 mg + NS 50 mL | 1/week | > 1 cycles, or pleural effusion disappeared |
Fang S 2011 [26] | 30 | 30 | Cisplatin: 60 mg + NS 40 mL IL-2: 2 million units+NS 40 mL | Cisplatin 60 mg + NS 40 mL | 1/week | > 3 cycles, or pleural effusion disappeared |
Xueling L 2011 [27] | 34 | 34 | Cisplatin: 60 mg + NS 50 mL IL-2: 2 million units+NS 50 mL | Cisplatin 60 mg + NS 50 mL | 1/week | > 3 cycles, or pleural effusion disappeared |
Yan Q 2011 [28] | 41 | 35 | Cisplatin: 60 mg + NS 40 mL IL-2: 2 million units+NS 40 mL | Cisplatin 60 mg + NS 40 mL | 1/week | > 3 cycles, or pleural effusion disappeared |
Li J 2013 [29] | 38 | 35 | Cisplatin: 60-80 mg + NS 50 mL IL-2: 1–2 million units+NS 20 mL | Cisplatin 60-80 mg + NS 50 mL | 1/week | > 3 cycles, or pleural effusion disappeared |
Lijie H 2014 [30] | 30 | 30 | Cisplatin: 40-60 mg + NS 50 mL IL-2: 2 million units+NS 50 mL | Cisplatin 40-60 mg + NS 50 mL | 1/week | > 2 cycles, or pleural effusion disappeared |
Miao H 2016 [31] | 31 | 30 | Cisplatin: 60 mg + NS 50 mL IL-2: 2–3 million units+NS 30 mL | Cisplatin 60 mg + NS 50 mL | 1/week | > 3 cycles, or pleural effusion disappeared |
Baohua Y 2017 [32] | 33 | 33 | Cisplatin: 70-80 mg + NS 50 mL IL-2: 2–3 million units+NS 30 mL | Cisplatin 70-80 mg + NS 50 mL | 1/week | > 3 cycles, or pleural effusion disappeared |